BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37066362)

  • 1. Genetic modifiers of APOBEC-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Bray N; Mitchell D; Lobachev K; Roberts SA
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic inhibitors of APOBEC3B-induced mutagenesis.
    Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
    Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
    Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
    Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avoidance of APOBEC3B-induced mutation by error-free lesion bypass.
    Hoopes JI; Hughes AL; Hobson LA; Cortez LM; Brown AJ; Roberts SA
    Nucleic Acids Res; 2017 May; 45(9):5243-5254. PubMed ID: 28334887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
    Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
    Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
    Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
    Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3B cytidine deaminase targets the non-transcribed strand of tRNA genes in yeast.
    Saini N; Roberts SA; Sterling JF; Malc EP; Mieczkowski PA; Gordenin DA
    DNA Repair (Amst); 2017 May; 53():4-14. PubMed ID: 28351647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase.
    Serebrenik AA; Starrett GJ; Leenen S; Jarvis MC; Shaban NM; Salamango DJ; Nilsen H; Brown WL; Harris RS
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22158-22163. PubMed ID: 31611371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
    Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
    Vural S; Simon R; Krushkal J
    Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
    Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
    Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
    Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
    Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
    J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation.
    Pan JW; Zabidi MMA; Chong BK; Meng MY; Ng PS; Hasan SN; Sandey B; Bahnu S; Rajadurai P; Yip CH; Rueda OM; Caldas C; Chin SF; Teo SH
    Int J Cancer; 2021 May; 148(10):2489-2501. PubMed ID: 33423300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking bad: The mutagenic effect of DNA repair.
    Chen J; Furano AV
    DNA Repair (Amst); 2015 Aug; 32():43-51. PubMed ID: 26073774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
    Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
    Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMCES Maintains Replication Fork Progression and Prevents Double-Strand Breaks in Response to APOBEC Deamination and Abasic Site Formation.
    Mehta KPM; Lovejoy CA; Zhao R; Heintzman DR; Cortez D
    Cell Rep; 2020 Jun; 31(9):107705. PubMed ID: 32492421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.
    Glaser AP; Fantini D; Wang Y; Yu Y; Rimar KJ; Podojil JR; Miller SD; Meeks JJ
    Oncotarget; 2018 Jan; 9(4):4537-4548. PubMed ID: 29435122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.